Cardiovascular Safety and Efficacy of Nebulized Glycopyrrolate/eFlow CS in Phase 3 Trials of Patients With Moderate to Very Severe COPD

      SESSION TITLE: COPD 2
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect